Michigan to limit Medicaid coverage for weight loss drugs to people with diabetes, morbid obesity

GLP-1 receptor agonists like Wegovy, Saxenda and Zepbound will be restricted in Michigan “exclusively to individuals classified as morbidly obese” under the new budget, with coverage contingent on the failure of other weight loss interventions to prevent higher-cost bariatric surgery. The state’s M...

Redirecting to full article...